With over 35 years of experience in the courtroom, boardroom, and alternative dispute resolution (ADR) venues, Allen Waxman has been a trial lawyer, national counsel in mass tort cases, counselor to the C-suite and boards, and the CEO of a dispute resolution organization. He brings that experience to resolution efforts in large commercial and mass claims matters. At the same time, he also leads the firm’s efforts at AI transformation while also providing legal guidance to clients in their use of AI and for the firm’s AI Innovation Team, PiperAI, in its efforts to devel...
With over 35 years of experience in the courtroom, boardroom, and alternative dispute resolution (ADR) venues, Allen Waxman has been a trial lawyer, national counsel in mass tort cases, counselor to the C-suite and boards, and the CEO of a dispute resolution organization. He brings that experience to resolution efforts in large commercial and mass claims matters. At the same time, he also leads the firm’s efforts at AI transformation while also providing legal guidance to clients in their use of AI and for the firm’s AI Innovation Team, PiperAI, in its efforts to develop AI-enabled applications for the firm’s lawyers and clients.
Allen’s diverse skill set was developed as the head of litigation and General Counsel of Pfizer, the General Counsel and a business unit leader of Market Access at Eisai (a Japanese-based pharma company), and General Counsel of Roivant Sciences, a biotech startup. He also most recently led the International Institute for Conflict Prevention and Resolution (CPR), a not-for-profit comprised of corporate, law firm and other members from around the world, focusing on dispute management across industry sectors, such as healthcare and life sciences, energy, oil and gas, insurance, and technology. CPR developed tools for more effective, efficient ways to resolve disputes and prevent them where possible and provided mediation, arbitration, and other ADR services.
Previously, Allen was a partner at two prominent law firms where he led trial teams, served as national counsel in pharmaceutical product liability cases, developed and led compliance diagnostics and risk management reviews, built a life sciences practice group, and executed dispute resolution strategies.
